Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2385 • 2012 ACR/ARHP Annual Meeting
Prognostic Impact of HLA-B^*51 and HLA–A^*26:01 On Ocular Behcet’s Disease
Jun Won Park¹, Eun Ha Kang², Hye Won Kim¹, Chaerin Park³, Hyeong Gon Yu³, Eun Young Lee¹, Yun Jong Lee⁴, Eun Bong Lee¹ and Yeong Wook Song⁵, ¹Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Ophthalmology, Seoul National University Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: To investigate the prognostic implication of HLA-B*51 and HLA-A*26:01on visual outcome in Korean Behcet’s disease (BD) patients with uveitis. Methods: Seventy-seven Korean BD patients…
Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting
Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Sho Ueda, Hiroshi Tsukamoto, Yasushi Inoue, Masahiro Ayano, Satomi Hisamoto, Naoko Ueki, Atsushi Tanaka, Shun-ichiro Ohta, Naoyasu Ueda, Yojiro Arinobu, Hiroaki Niiro, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…
Abstract Number: 2394 • 2012 ACR/ARHP Annual Meeting
Fibromyalgia in Behçet’s Disease Is Associated with Disease Activity
Meryem Can¹, Fatma Alibaz-Öner², Sibel Yılmaz-Öner³, Birkan İlhan⁴, Tülin Ergun⁵, Gonca Mumcu⁶ and Haner Direskeneli⁷, ¹Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Department of Rheumatology, Marmara University School of Medicine, Turkey, ³Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁴Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁵Dermatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Studies on the relationship between Fibromyalgia (FM), a generalized pain disorder with up to 2% prevelance and Behcet’s Disease (BD), a systemic, inflammatory vasculitis,…
Abstract Number: 2369 • 2012 ACR/ARHP Annual Meeting
Aspects of Innate Immunity in Behçet´s Disease: A Model of Autoinflammatory Disease?
Sandro F. Perazzio¹, Paulo Vitor Soeiro Pereira², Alexandre Wagner S. de Souza³, Antonio Condino-Neto² and Luis Eduardo C. Andrade⁴, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis of unknown etiopathogenesis. Increased neutrophil activation has been previously shown in BD patients and it is unclear…
Abstract Number: 2370 • 2012 ACR/ARHP Annual Meeting
A Genome-Wide DNA Methylation Study Identifies Significant Epigenetic Changes Across the Genome and in Multiple HLA Loci in Behcet’s Disease
Haner Direskeneli¹, Patrick S. Coit², Filiz Ture-Ozdemir¹, Fatma Alibaz-Oner¹, Guher Saruhan-Direskeneli³, Matlock A. Jeffries⁴ and Amr H. Sawalha², ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Medicine, University of Oklahoma and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Behcet’s disease (BD) is a systemic vasculitis of poorly understood etiology. Herein, we study the DNA methylome in BD for the first time and…
Abstract Number: 2371 • 2012 ACR/ARHP Annual Meeting
The Unmet Need in Behcet’s Disease: Most Patients Are Not in Complete Remission in the Long-Term Follow-up
Fatma Alibaz-Oner¹, Gonca Mumcu², Gülsen Ozen³, Zeynep Kubilay⁴, Meryem Can¹, Sibel Yýlmaz Oner¹, Tülin Ergun⁵ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ³Rheumatology, Marmara University School of Medicine., Istanbul, Turkey, ⁴Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Dermatology, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: The nature of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing course is unsufficiently explored. As complete remission should be aimed in…
Abstract Number: 2372 • 2012 ACR/ARHP Annual Meeting
Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Maki Takayama², Yoshitaka Kimura², Kurumi Asako², Hajime Kono², Yasuo Ono¹ and Shunsei Hirohata³, ¹Department of Microbiology and Immunology, Teikyo University Shool of Medicine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose : CNS involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB) based…
Abstract Number: 2373 • 2012 ACR/ARHP Annual Meeting
The Clinical Course of the Acute Deep Vein Thrombosis of the Legs in Behçet’s Syndrome
Yesim Ozguler¹, Melike Melikoglu², Firat Cetinkaya³, Serdal Ugurlu⁴, Emire Seyahi⁵, Koray Tascilar⁶ and Hasan Yazici⁷, ¹Cerrahpasa Medical Faculty, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Radiology, Colormed Radiology Center, Istanbul, Turkey, ⁴Rheumatology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁵Rheumatology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁶University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ⁷Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey
Background/Purpose: 15-50% of patients with Behçet’s syndrome have vascular involvement (BS). Deep vein thrombosis is the most common form with lower extremity deep vein thrombosis…
Abstract Number: 2374 • 2012 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behcet’s Syndrome: Experience in A Dedicated Center
Ibrahim Hatemi¹, Gulen Hatemi², Yusuf Erzin¹, Aykut Ferhat Celik¹ and Hasan Yazici³, ¹Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey
Background/Purpose: Gastrointestinal involvement can be a severe complication resulting in perforation and massive bleeding. Controlled data regarding treatment is lacking and long term prognosis is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].